# Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

> **NCT06492915** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Chipscreen Biosciences, Ltd.** · enrollment: 42 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Chiauranib
- **DRUG:** Albumin-paclitaxel Injection
- **DRUG:** Gemcitabine Injection

## Key facts

- **NCT ID:** NCT06492915
- **Lead sponsor:** Chipscreen Biosciences, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-13
- **Primary completion:** 2026-05-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06492915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06492915, "Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT06492915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*